We are pleased to announce that our Director of Radiopharmaceuticals, Dr Sidney Yu, has been awarded the Fellowship of the Royal Society of Chemistry (FRSC).

Dr Sidney Yu
PhD, FRSC

The Fellowship of the Royal Society of Chemistry (FRSC) is one of the most prestigious awards conferred by the Royal Society of Chemistry (RSC) in the United Kingdom. Existing Fellows include award winning scientists and Nobel prize winners.

Dr Sidney has been instrumental in the development of radiochemistry and nuclear medicine in Singapore and Southeast Asia. A senior and highly respected radiochemist, he established Singapore’s first GMP-compliant cyclotron and radiochemistry laboratory, attracting major investments from multinational pharmaceutical companies such as Roche, Bayer, and Merck. He has driven key advances in targeted radionuclide therapies, including Selective Internal Radiation Therapy (SIRT), the first radiochemo-embolization therapy for unresectable liver cancer, and the introduction of Peptide Receptor Radionuclide Therapy (PRRT). Since joining SAM in 2018 as Director of Radiopharmaceuticals, Dr Sidney has built the radiopharmaceutical laboratory from the ground up, led the introduction of novel radiotracers with strong clinical potential—including N-13 ammonia and Ac-225 PSMA—and positioned SAM as one of the few centres in Southeast Asia capable of producing short half-life radiotracers and serving as a trusted clinical research partner for global theranostics development.

Heartiest congratulations Dr Sidney from management, doctors and staff of Singapore Institute of Advanced Medicine Holdings.